Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Atacicept Autoinjector Combination, Atacicept
Vera Therapeutics
Treatment of IgAN
1 trial -
Atorvastatin
The First People's Hospital of Lianyungang
Myocardial Infarction
1 trial -
Aumolertinib
The First People's Hospital of Lianyungang
Lung Cancer
1 trial -
Autologous CD5 CAR T-cells
The First People's Hospital of Lianyungang
T-Cell Acute Lymphocytic Leukemia
1 trial -
Azacitidine
The First People's Hospital of Lianyungang
Philadelphia Chromosome
1 trial -
Azacitidine (AZA) with Ruxolitinib
The First People's Hospital of Lianyungang
MDS/MPN
1 trial -
Azacitidine Injection
The First People's Hospital of Lianyungang
B Acute Lymphoblastic Leukemia
1 trial -
Azacitidine in Combination With Venetoclax
The First People's Hospital of Lianyungang
Hematologic Malignancy
1 trial -
BGB-A317
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
BM-MSCs
The First People's Hospital of Lianyungang
Kidney Transplantation
2 trials -
BOTOX 100 Allergan Units Powder for Solution for Injection
Disc Medicine
postoperative pancreatic fistulas
1 trial -
Baritinib
The First People's Hospital of Lianyungang
Intracerebral Hemorrhage
1 trial -
Becotatug Vedotin
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma (NPC)
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Malignant Pleural Effusion
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Lung, Carcinoma
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
Bevacizumab Biosimilar IBI305
The First People's Hospital of Lianyungang
Post-orthotopic Liver Transplantation
1 trial -
Bevacizumab combined with Oxaliplatin and TAS-102
The First People's Hospital of Lianyungang
Advanced Colorectal Cancer
1 trial -
Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Bexarotene
LIGAND PHARMACEUTICALS INC
Sarcoma, Kaposi
1 trial -
Bexarotene
LIGAND PHARMACEUTICALS INC
Lung Cancer
1 trial -
Bexarotene (targretin)
LIGAND PHARMACEUTICALS INC
Carcinoma, Non-small-cell Lung
1 trial -
Bexarotene 1% gel
LIGAND PHARMACEUTICALS INC
Parapsoriasis
1 trial -
Bexarotene/NBUVB vs placebo NBUVB
LIGAND PHARMACEUTICALS INC
Psoriasis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources